NYSEAMERICAN:CANF - Can Fite Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.2939 -0.04 (-3.00 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$1.2939
Today's Range$1.29 - $1.33
52-Week Range$1.24 - $2.75
Volume47,137 shs
Average Volume131,474 shs
Market Capitalization$32.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94

About Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma logoCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Debt-to-Equity RatioN/A
Current Ratio7.29
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,453.03%
Return on Equity-57.94%
Return on Assets-32.52%

Miscellaneous

Employees7
Outstanding Shares19,980,000

Can Fite Biopharma (NYSEAMERICAN:CANF) Frequently Asked Questions

What is Can Fite Biopharma's stock symbol?

Can Fite Biopharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were Can Fite Biopharma's earnings last quarter?

Can Fite Biopharma (NYSEAMERICAN:CANF) released its quarterly earnings results on Friday, March, 23rd. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.09. The biotechnology company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. Can Fite Biopharma had a negative return on equity of 57.94% and a negative net margin of 2,453.03%. View Can Fite Biopharma's Earnings History.

When is Can Fite Biopharma's next earnings date?

Can Fite Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Can Fite Biopharma.

What price target have analysts set for CANF?

2 brokerages have issued 12-month target prices for Can Fite Biopharma's stock. Their predictions range from $6.00 to $7.00. On average, they anticipate Can Fite Biopharma's stock price to reach $6.50 in the next year. View Analyst Ratings for Can Fite Biopharma.

Who are some of Can Fite Biopharma's key competitors?

Who are Can Fite Biopharma's key executives?

Can Fite Biopharma's management team includes the folowing people:
  • Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

Has Can Fite Biopharma been receiving favorable news coverage?

News articles about CANF stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Can Fite Biopharma earned a coverage optimism score of 0.08 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Can Fite Biopharma's major shareholders?

Can Fite Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (8.34%), SABBY MANAGEMENT, LLC (8.34%), Anson Funds Management LP (6.79%) and Sabby Management LLC (6.15%). View Institutional Ownership Trends for Can Fite Biopharma.

Which institutional investors are buying Can Fite Biopharma stock?

CANF stock was purchased by a variety of institutional investors in the last quarter, including Anson Funds Management LP and Sabby Management LLC. View Insider Buying and Selling for Can Fite Biopharma.

How do I buy shares of Can Fite Biopharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Can Fite Biopharma's stock price today?

One share of CANF stock can currently be purchased for approximately $1.2939.

How big of a company is Can Fite Biopharma?

Can Fite Biopharma has a market capitalization of $32.28 million. Can Fite Biopharma employs 7 workers across the globe.

How can I contact Can Fite Biopharma?

Can Fite Biopharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for Can Fite Biopharma (CANF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Can Fite Biopharma (NYSEAMERICAN:CANF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Can Fite Biopharma in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 402.36%. The high price target for CANF is $7.00 and the low price target for CANF is $6.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.50$6.50$6.50
Price Target Upside: 402.36% upside311.39% upside195.45% upside314.01% upside

Can Fite Biopharma (NYSEAMERICAN:CANF) Consensus Price Target History

Price Target History for Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma (NYSEAMERICAN:CANF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/9/2018Maxim GroupReiterated RatingBuy ➝ Hold$7.00View Rating Details
2/1/2018HC WainwrightReiterated RatingBuy$6.00View Rating Details
10/19/2016Roth CapitalReiterated RatingBuyView Rating Details
8/29/2016Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 5/20/2016 forward)

Earnings

Can Fite Biopharma (NYSEAMERICAN:CANF) Earnings History and Estimates Chart

Earnings by Quarter for Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma (NYSEAMERICAN CANF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018        
3/23/2018Q4 2017($0.15)($0.06)$0.20 million$0.11 millionViewN/AView Earnings Details
11/27/2017Q3 2017($0.13)($0.04)$0.08 million$0.59 millionViewN/AView Earnings Details
9/1/2017Q2 2017($0.13)($0.12)$0.07 million$0.08 millionViewN/AView Earnings Details
5/30/2017Q1 2017($0.09)($0.08)$0.07 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.08)($0.14)ViewN/AView Earnings Details
11/25/2016Q3 2016($0.12)($0.18)$0.09 million$0.06 millionViewN/AView Earnings Details
8/26/2016Q2 2016($0.14)($0.08)$0.05 millionViewN/AView Earnings Details
5/31/2016Q116($0.09)($0.12)$0.06 millionViewN/AView Earnings Details
4/1/2016Q4 2015($0.07)$0.06$0.03 millionViewN/AView Earnings Details
11/27/2015Q3 2015($0.08)($0.30)$0.07 millionViewN/AView Earnings Details
8/27/2015Q2 2015($0.07)($0.14)$0.07 millionViewN/AView Earnings Details
5/29/2015Q115($0.12)($0.04)ViewN/AView Earnings Details
4/8/2015($0.15)($0.20)ViewN/AView Earnings Details
3/27/2015Q4 2014($0.15)($0.20)ViewN/AView Earnings Details
12/2/2014($0.24)($0.10)ViewN/AView Earnings Details
9/3/2014($0.36)($0.20)ViewN/AView Earnings Details
5/30/2014($0.23)($0.22)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.23)($0.44)ViewN/AView Earnings Details
11/29/2013Q3 2013($0.28)$0.20ViewN/AView Earnings Details
8/29/2013Q2 2013($0.21)($0.26)ViewN/AView Earnings Details
5/30/2013Q1 2013($0.21)($0.41)ViewN/AView Earnings Details
11/11/2012Q3 2012($0.21)$0.25ViewN/AView Earnings Details
8/30/2012Q2 2012($0.21)($0.26)ViewN/AView Earnings Details
5/31/2012Q1 2012($0.21)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Can Fite Biopharma (NYSEAMERICAN:CANF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Can Fite Biopharma (NYSEAMERICAN CANF) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 5.12%
Insider Trading History for Can Fite Biopharma (NYSEAMERICAN:CANF)
Institutional Ownership by Quarter for Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma (NYSEAMERICAN CANF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Can Fite Biopharma (NYSEAMERICAN CANF) News Headlines

Source:
DateHeadline
Can-Fites Piclidenoson Mechanism of Action in Psoriasis Published in Journal of Immunology ResearchCan-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
finance.yahoo.com - April 25 at 8:43 AM
Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018
finance.yahoo.com - April 13 at 8:57 AM
Can Fite Biopharma (CANF) PT Set at $6.00 by HC WainwrightCan Fite Biopharma (CANF) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - April 10 at 11:38 PM
Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical ...Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical ...
www.businesswire.com - April 9 at 5:00 PM
Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
finance.yahoo.com - April 9 at 8:55 AM
HC Wainwright Analysts Give Can Fite Biopharma (CANF) a $6.00 Price TargetHC Wainwright Analysts Give Can Fite Biopharma (CANF) a $6.00 Price Target
www.americanbankingnews.com - April 2 at 8:40 PM
HC Wainwright Reiterates "Buy" Rating for Can Fite Biopharma (CANF)HC Wainwright Reiterates "Buy" Rating for Can Fite Biopharma (CANF)
www.americanbankingnews.com - April 2 at 12:26 PM
Can-Fite to Present at the MicroCap ConferenceCan-Fite to Present at the MicroCap Conference
finance.yahoo.com - March 28 at 8:59 AM
Can Fite Biopharma Ltd (CANF) Short Interest Down 63.1% in MarchCan Fite Biopharma Ltd (CANF) Short Interest Down 63.1% in March
www.americanbankingnews.com - March 27 at 1:02 AM
Can-Fite Biopharma net loss improves in FY 2017Can-Fite Biopharma net loss improves in FY 2017
seekingalpha.com - March 24 at 9:13 AM
Can-Fite Reports 2017 Financial Results & Provides Clinical Update ... - Business Wire (press release)Can-Fite Reports 2017 Financial Results & Provides Clinical Update ... - Business Wire (press release)
www.businesswire.com - March 23 at 5:14 PM
BRIEF-Can-Fite Reports 2017 Financial ResultsBRIEF-Can-Fite Reports 2017 Financial Results
www.reuters.com - March 23 at 8:48 AM
Form SC 13G Can-Fite BioPharma Ltd. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.comForm SC 13G Can-Fite BioPharma Ltd. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
www.streetinsider.com - March 14 at 9:18 AM
Can-Fite to Present at the NASH 2nd Annual HC Wainwright Investor Conference - Business Wire (press release)Can-Fite to Present at the NASH 2nd Annual HC Wainwright Investor Conference - Business Wire (press release)
www.businesswire.com - March 14 at 9:18 AM
Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor ConferenceCan-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
finance.yahoo.com - March 14 at 9:18 AM
Can-Fite secures $5M private capital raise; shares down 16% premarketCan-Fite secures $5M private capital raise; shares down 16% premarket
seekingalpha.com - March 9 at 6:16 PM
Can-Fite BioPharma (CANF) Reports $5 Million Registered Direct OfferingCan-Fite BioPharma (CANF) Reports $5 Million Registered Direct Offering
www.streetinsider.com - March 9 at 6:16 PM
Can-Fite BioPharma Announces $5 Million Registered Direct OfferingCan-Fite BioPharma Announces $5 Million Registered Direct Offering
finance.yahoo.com - March 9 at 6:16 PM
Can Fite Biopharmas (CANF) "Hold" Rating Reaffirmed at Maxim GroupCan Fite Biopharma's (CANF) "Hold" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - March 9 at 4:03 PM
Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30 - Business Wire (press release)Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30 - Business Wire (press release)
www.businesswire.com - March 7 at 8:51 AM
Can-Fite to Present at the Inaugural LD Micro Virtual Conference - Business Wire (press release)Can-Fite to Present at the Inaugural LD Micro Virtual Conference - Business Wire (press release)
www.businesswire.com - March 6 at 8:42 AM
Form 6-K Can-Fite BioPharma Ltd. For: Mar 06 - StreetInsider.comForm 6-K Can-Fite BioPharma Ltd. For: Mar 06 - StreetInsider.com
www.streetinsider.com - March 6 at 8:42 AM
Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH ConferenceCan-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 8:42 AM
Can-Fite to Present at the Inaugural LD Micro Virtual ConferenceCan-Fite to Present at the Inaugural LD Micro Virtual Conference
finance.yahoo.com - March 5 at 8:45 AM
Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate NamodenosonCan Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
finance.yahoo.com - February 28 at 5:38 PM
Short Interest in Can Fite Biopharma Ltd (CANF) Declines By 29.5%Short Interest in Can Fite Biopharma Ltd (CANF) Declines By 29.5%
www.americanbankingnews.com - February 28 at 1:08 AM
Can-Fite (CANF) Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA, other Regulatory AuthoritiesCan-Fite (CANF) Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA, other Regulatory Authorities
www.streetinsider.com - February 23 at 8:49 AM
BRIEF-Can Fite Submits Safety Reports To FDABRIEF-Can Fite Submits Safety Reports To FDA
www.reuters.com - February 22 at 5:19 PM
Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety ProfileCan Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
finance.yahoo.com - February 22 at 8:44 AM
Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for NamodenosonCan-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
finance.yahoo.com - February 12 at 9:36 AM
Can Fite Biopharma Ltd (CANF) Sees Large Growth in Short InterestCan Fite Biopharma Ltd (CANF) Sees Large Growth in Short Interest
www.americanbankingnews.com - February 9 at 8:28 PM
Can Fite Biopharmas (CANF) "Buy" Rating Reaffirmed at HC WainwrightCan Fite Biopharma's (CANF) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM
Can-Fite to Present at BIO CEO & Investor ConferenceCan-Fite to Present at BIO CEO & Investor Conference
finance.yahoo.com - January 31 at 10:02 AM
BRIEF-Can-Fite Receives $2.2 Mln From Gebro Holdings As Part Of Distribution AgreementBRIEF-Can-Fite Receives $2.2 Mln From Gebro Holdings As Part Of Distribution Agreement
www.reuters.com - January 25 at 9:38 AM
Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European CountriesCan-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
finance.yahoo.com - January 25 at 9:38 AM
Can Fite Biopharma Ltd (CANF) Sees Significant Increase in Short InterestCan Fite Biopharma Ltd (CANF) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 24 at 6:08 PM
Can-Fite BioPharma (CANF) Announces Milestones for 2018 - StreetInsider.comCan-Fite BioPharma (CANF) Announces Milestones for 2018 - StreetInsider.com
www.streetinsider.com - January 11 at 9:09 AM
Can Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in DecemberCan Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in December
www.americanbankingnews.com - January 10 at 5:38 PM
Can-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro HoldingsCan-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro Holdings
www.streetinsider.com - January 9 at 8:58 AM
Can Fite Biopharma (CANF) Earns "Buy" Rating from Maxim GroupCan Fite Biopharma (CANF) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - January 8 at 5:28 PM
Can-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs - Baystreet.caCan-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs - Baystreet.ca
www.baystreet.ca - January 8 at 5:19 PM
Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings - Business Wire (press release)Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings - Business Wire (press release)
www.businesswire.com - January 8 at 5:19 PM
Can-Fite (CANF) Enters Pact with Hadassah Medical Center to ... - StreetInsider.comCan-Fite (CANF) Enters Pact with Hadassah Medical Center to ... - StreetInsider.com
www.streetinsider.com - January 3 at 5:15 PM
Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASHCan-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
finance.yahoo.com - January 3 at 8:05 AM
Can-Fite (CANF) Reports on the Progress of Its Phase II Liver ... - StreetInsider.comCan-Fite (CANF) Reports on the Progress of Its Phase II Liver ... - StreetInsider.com
www.streetinsider.com - December 18 at 5:12 PM
Maxim Group Analysts Give Can-Fite BioPharma (CANF) a $7.00 Price TargetMaxim Group Analysts Give Can-Fite BioPharma (CANF) a $7.00 Price Target
www.americanbankingnews.com - December 18 at 3:28 PM
Research Analysts Set Expectations for Can-Fite BioPharma Ltd.s FY2017 Earnings (CANF)Research Analysts Set Expectations for Can-Fite BioPharma Ltd.'s FY2017 Earnings (CANF)
www.americanbankingnews.com - December 4 at 2:22 AM
Can-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with NamodenosonCan-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
www.streetinsider.com - November 28 at 5:12 PM
Can-Fite BioPharma Ltd. (CANF) Short Interest Down 59.2% in NovemberCan-Fite BioPharma Ltd. (CANF) Short Interest Down 59.2% in November
www.americanbankingnews.com - November 27 at 9:58 PM
Can-Fites Former Subsidiary OphthaliX Successfully Completes ... - Business Wire (press release)Can-Fite's Former Subsidiary OphthaliX Successfully Completes ... - Business Wire (press release)
www.businesswire.com - November 17 at 7:36 PM

SEC Filings

Can Fite Biopharma (NYSEAMERICAN:CANF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Can Fite Biopharma (NYSEAMERICAN:CANF) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Can Fite Biopharma (NYSEAMERICAN CANF) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.